RICHMOND, Va. (WRIC) — A new manufacturing process is on track to make developing HIV-prevention medication more affordable and potentially decrease new HIV infections in hard-hit countries. Virginia ...
As the HIV research community prepares to convene for the Conference on Retroviruses and Opportunistic Infections (CROI) 2026 ...
Drug conjugates (ADCs) developed at Institute of Science Tokyo combine a CD4 mimic with neutralizing antibodies for enhanced suppression of human immunodeficiency virus (HIV) infection. By targeting ...
“This strategy of [switching to bictegravir/emtricitabine/tenofovir alafenamide] is an appealing one for reducing severe interactions, toxicity and pill burden in ...
The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.
A novel HIV vaccine candidate induces neutralising antibodies after a single dose in primates, potentially accelerating HIV ...
Hilton Humphries does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...
The use of opioids alone does not significantly impair cognition in patients with HIV infection, but the combined use of opioids and antidepressants is linked to poorer neurocognitive performance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results